Abstract:Abstract Abstract 4377 Background: Myeloid Sarcoma (MS) is a rare neoplasm composed of immature myeloid cells occurring in any extramedullary organ most commonly in the skin, bone and lymph node. It may develop independently or concurrently with acute myeloid leukemia (AML), myeloproliferative disorder (MPD) or myelodysplastic syndrome (MDS). Some reports have described MS while most of them were one case report. In this study we retrospectively analyzed the clinical characteristics, treatment approaches and prognosis of 18 MS patients in our single center. Methods: between January 2003 and March 2010, eighteen MS patients were included in this study. The diagnosis depends on histological features and immunohistochemical results. All pathology specimens were routinely processed and examined by morphology. Immunohistochemical stains were performed on paraffin-embedded sections with monoclonal antibodies including MPO, CD3, CD20, CD79a, CD45, CD34, CD117, CD43. At the same time bone marrow aspiration were routinely examined. Disease morphology was determined according to the French-American – British(FAB) classification. After patients had comfirmed diagnosis with MS, they received cytarabine plus idarubicin or homoharringtonine for induction and consolidation chemotherapy. All the statistical analyses were performed using Kaplan-Meier. Results: among the 18 patients, the proportion of male and female was 1:1. Median age at diagnosis was 31.5 years (range 18–67). The usual involvement sites were skin (25%), lymph node (20%), breast (15%), uterus and cervix (15%). In total ten of the eighteen patients (55.6%) preceded AML without abnormality in peripheral blood and bone marrow while five patients concurrently developed AML-M2 and three (22.2%) were initially misdiagnosed as two were mistaken for Non-Hodgkin's lymphoma and the other for myeloma. In total 14 of 18 patients were examined by immunohistochemistry. The positive rate of MPO was 92.9% and other myeloid related markers were also strongly positive whereas lymphoid related markers were negative which were accord with biologic properties of myeloid cells. All the patients received chemotherapy. 10 patients without bone marrow involvement achieved complete disappearance of MS. Of these, 5 (50%) patients still kept complete remission after 1 year, 3 progressed to AML after six, eight and sixty-two months respectively; 2 died after two months after definite diagnoses of AML. As for the 6 patients with bone-marrow involvement undgone chemotherapy, 5 (83.3%) achieved complete bone-marrow remission but 3 of them relapsed at the points of seven,eleven and eighteen months, respectively. 4-year EFS and OS were longer in non-leukemic MS patients than in MS cases with bone-marrow involvement using Kaplan-Meier analyses. Conclusion: this study showed myeloid sarcoma could develop in various kinds of populations with easy misdiagnosis. Non-leukemic MS should be the beginning stage of AML. It is necessary to treat patients who have non-leukemic MS by classic chemical therapy for AML as early as possible. As such a study is limited by relatively small sample size, more clinical prospective trials in multiple centers should be carried out worldwide. Disclosures: No relevant conflicts of interest to declare.

Myeloid Sarcomas with CBFA2T3 : GLIS2 Fusion: Clinicopathologic Characterization of 4 Cases Mimicking Small Round Cell Tumors

Novel ATXN1/ATXN1L::NUTM2A Fusions Identified in Aggressive Infant Sarcomas with Gene Expression and Methylation Patterns Similar to CIC-rearranged Sarcoma

Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene

Myeloid sarcoma with RBM15::MRTFA (MKL1) mimicking vascular neoplasm

Cytohistological findings and diagnostic challenges in rare pediatric pulmonary mesenchymal malignancies: A report of two cases

Pediatric Erythroid Sarcoma Diagnostically Confirmed by Identification of a Recurrent NFIA::CBFA2T3 Fusion

Myofibroma with Atypical Features can Mimic Low-Grade Myofibroblastic Sarcoma: Two Paediatric Cases

Sarcomatoid Morphology in Pediatric Langerhans Cell Neoplasm Does Not Always Predict Aggressive Clinical Course

Misdiagnosis of synovial sarcoma - cellular myofibroma with SRF-RELA gene fusion: A case report

Update on Superficial Spindle Cell Mesenchymal Tumors in Children

Non-malignant fibroblastic/myofibroblastic tumors in pediatric age group: Clues and pitfalls to the cytological diagnosis

Myeloid Sarcoma Type of Acute Promyelocytic Leukemia With a Cryptic Insertion of RARA Into FIP1L1: The Clinical Utility of NGS and Bioinformatic Analyses

Mandibular rhabdomyosarcoma with TFCP2 rearrangement and osteogenic differentiation: a case misdiagnosed as fibrous dysplasia or low-grade central osteosarcoma

Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas

An isolated sacral promyelocytic sarcoma in a child: A rare case report with emphasis on cytomorphology

Mediastinal Myeloid Sarcoma with TP53 Mutation Preceding Acute Myeloid Leukemia with a PICALM-MLLT10 Fusion Gene

Diagnostic and Therapeutic Implications of a FUS::TFCP2 Fusion and ALK Activation in a Metastatic Rhabdomyosarcoma

Aggressive Pediatric Primitive Round Cell Tumors with MN1::ZNF341 Fusion: A Mimic of Neuroblastoma

Fusion‐driven cutaneous and superficial mesenchymal and adnexal tumors—A clinicopathologic and molecular study of 15 cases, including a novel case of ACTB::ZMIZ2‐rearranged adnexal carcinoma

A Case of Myxoid Pleomorphic Liposarcoma with Rhabdoid Cells: A Diagnostic Pitfall

Myeloid Sarcoma: a Clinical Report of 18 Cases